Table 6.

Diagnostic performances of combinations of four serum biomarkers for differentiating HCC from liver disease in patients with AFP < 20 ng/mL

Markers	AUC	Sensitivity (Sn)	Specificity (Sp)	Sn + Sp	PPV	NPV
ALT+AST	0.646 (0.591–0.698)	0.737 (0.66–0.800)	0.550 (0.470–0628)	1.287	0.632 (0.560–0.699)	0.667 (0.5794–0.744)
NLR + ALT	0.682 (0.628–0.732)	0.500 (0.423–0.578)	0.873 (0.809–0.917)	1.423	0.804 (0.714–0.871)	0.645 (0.558–0.688)
NLR + AST	0.666 (0.611–0.716)	0.821 (0.753–0.873)	0.503 (0.424–0.583)	1.324	0.634 (0.565–0.697)	0.728 (0.635–0.805)
NLR + AST + ALT	0.666 (0.611–0.716)	0.821 (0.753–0.873)	0.503 (0.424–0.583)	1.324	0.634 (0.565–0.697)	0.728 (0.635–0.805)

HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AFP, alpha-fetoprotein; NLR, neutrophil-granulocyte ratio; AUC, area under the receiver operating characteristic curve